Fig 1: Importance of RHBDL2 in TARGET-OS cohort. (A) Kaplan-Meier survival curve showing survival probability of high- or low-expression RHBDL2; (B) The 1-year, 2-year, 3-year, 4-year, and 5-year survival ROC curves predicted by the expression of RHBDL2, with curves in different colors representing the AUC for different years; (C) The forest figure for Univariate and Multivariate Cox regression analyses of RHBDL2 and clinicopathologic features (Age, Sex); (D) The relationship of RHBDL2 with immune checkpoints in TARGET cohort; (E) Quantitative Real-time PCR. (A–C) Quantitative Real-time PCR assays using cell lines for RHBDL2; (F) The protein expression levels of ENO1 and CD44 in HK-2 cell control group and hyperglycemic group by Western blot; (G) The detection of RHBDL2 in tumor cells and normal cells by immunofluorescence.
Fig 2: Efficacy of OXS-signature for OS. (A) Heat map showing the relationship between five genes (RHBDL2, CGREF1, C2, CSAG1, and MAGEA12) in the OXS-signature and OS-scores distribution and its clinical characteristics; (B) Kaplan-Meier survival curve showing survival probability of high-OS-score or low-OS-score subgroups for TARGET-OS cohort, with the green curve representing the group with higher OS-scores, and the purple curve representing the group with lower OS-scores; (C) The 1-year, 2-year, 3-year, 4-year, and 5-year survival ROC curves predicted by the OXS-signature for TARGET-OS cohort, with curves in different colors referring to the AUC for different years; (D) Kaplan-Meier survival curve showing survival probability of high-OS-score or low-OS-score subgroups for GSE21257-OS cohort, with the green curve indicating the group with higher OS-scores, and the purple curve indicating the group with lower OS-scores; (E) The 1-year, 2-year, 3-year, 4-year, and 5-year survival ROC curves predicted by the OXS-signature for GSE21257-OS cohort, with curves in different colors representing the AUC for different years.
Supplier Page from Abcam for Recombinant Human RRP2 protein (His tag)